IRS2 and cancer: Insulin receptor substrate 2 (IRS2), that we found targeted simultaneously by 4 miRNAs, is a candidate driver oncogene frequently amplified in cancer with the ability to modulate and coordinate multiple signaling cascades, transmitting upstream signals to intracellular pathways, including the PI3K/AKT/mTOR and MAP kinase pathways [62].